

Pfizer's Best-In-Class European Manufacturing and Supply Network

Pfizer's ability to meet patient needs around the globe, especially during times of crisis, depends on our ability to maintain a supply chain that is both flexible and resilient.

We operate one of the most sophisticated supply chain systems in the industry, with:

- **40+** Pfizer-owned sites
- **200+** suppliers globally

This provides capacity and flexibility, where needed, and ensures the highest safety and quality standards in the industry.

For more than **170 years**, we have worked to make a difference for all who rely on us.

Making Medicines in Europe: Serving Patients in Europe and Around the World

With a presence here since the 1950's, Europe is home to:


18,000
COLLEAGUES



8,000 OF WHICH ARE IN MANUFACTURING


AS A KEY EXPORT HUB, **OVER 60%**
OF OUR MEDICINES ARE HANDLED IN EUROPE,
SUPPLYING PATIENTS IN **170+ COUNTRIES**

17 OPERATING R&D AND
MANUFACTURING SITES



THESE PRODUCE ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) AND FINISHED MEDICINES, RANGING FROM SMALL MOLECULES, TO STERILE INJECTABLE HOSPITAL PRODUCTS, TO VACCINES AND BIOLOGICS.

OUR SITES IN EUROPE
HANDLE **97% OF PFIZER**
MEDICINES SOLD HERE



85% OF THE APIs IN
OUR PATENTED
MEDICINES COME
FROM EUROPE

59



CONTRACT MANUFACTURERS

OUR **GLOBAL LOGISTICS CENTER** IN BELGIUM WORKS WITH

22 LOGISTICS SERVICE
PROVIDERS TO MAKE ALMOST

8,000 INTERNAL
SHIPMENTS

AND MORE THAN **600,000** CUSTOMER SHIPMENTS EVERY YEAR.

Scaling for Success

The recent COVID-19 pandemic has reinforced the strength and importance of our global network.

At the height of the crisis in Europe in Spring 2020, we implemented an unprecedented and comprehensive preparedness plan to control our site operations and meet the increased demands – **of 200%+** – for our medicines.

Our network of manufacturing sites was able to deliver meaningful quantities of products to meet patient needs. We shipped **17 critical medicines at over 150%** of forecast across Europe. In all, we added around **80 million units** of sterile injectable medicines to support the demand.

Pfizer is proud of our work with governments, hospitals and other healthcare institutions to help ensure patients have access to our medicines when they need them.

Pfizer is committed to our patients and looks towards partnerships with governments to address current and future challenges to meet patient needs.

Our Impact Stretches Across the Continent



August 2020